GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » PS Ratio

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) PS Ratio : 115.67 (As of May. 14, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cancer Prevention Pharmaceuticals's share price is $25.91. Cancer Prevention Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2016 was $0.22. Hence, Cancer Prevention Pharmaceuticals's PS Ratio for today is 115.67.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's PS Ratio or its related term are showing as below:

CPP's PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.21
* Ranked among companies with meaningful PS Ratio only.

Cancer Prevention Pharmaceuticals's Revenue per Sharefor the three months ended in Mar. 2016 was $0.19. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2016 was $0.22.

Back to Basics: PS Ratio


Cancer Prevention Pharmaceuticals PS Ratio Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals PS Ratio Chart

Cancer Prevention Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15
PS Ratio
- - -

Cancer Prevention Pharmaceuticals Quarterly Data
Dec13 Dec14 Mar15 Sep15 Dec15 Mar16
PS Ratio Get a 7-Day Free Trial - - - - -

Competitive Comparison of Cancer Prevention Pharmaceuticals's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cancer Prevention Pharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's PS Ratio falls into.



Cancer Prevention Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Cancer Prevention Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=25.91/0.224
=115.67

Cancer Prevention Pharmaceuticals's Share Price of today is $25.91.
Cancer Prevention Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.22.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Cancer Prevention Pharmaceuticals  (AMEX:CPP) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Cancer Prevention Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Headlines